Direkt zum Inhalt
Merck
  • Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

Gut microbiota modulate dendritic cell antigen presentation and radiotherapy-induced antitumor immune response.

The Journal of clinical investigation (2019-12-10)
Mireia Uribe-Herranz, Stavros Rafail, Silvia Beghi, Luis Gil-de-Gómez, Ioannis Verginadis, Kyle Bittinger, Sergey Pustylnikov, Stefano Pierini, Renzo Perales-Linares, Ian A Blair, Clementina A Mesaros, Nathaniel W Snyder, Frederic Bushman, Constantinos Koumenis, Andrea Facciabene
ZUSAMMENFASSUNG

Alterations in gut microbiota impact the pathophysiology of several diseases, including cancer. Radiotherapy (RT), an established curative and palliative cancer treatment, exerts potent immune modulatory effects, inducing tumor-associated antigen (TAA) cross-priming with antitumor CD8+ T cell elicitation and abscopal effects. We tested whether the gut microbiota modulates antitumor immune response following RT distal to the gut. Vancomycin, an antibiotic that acts mainly on gram-positive bacteria and is restricted to the gut, potentiated the RT-induced antitumor immune response and tumor growth inhibition. This synergy was dependent on TAA cross presentation to cytolytic CD8+ T cells and on IFN-γ. Notably, butyrate, a metabolite produced by the vancomycin-depleted gut bacteria, abrogated the vancomycin effect. In conclusion, depletion of vancomycin-sensitive bacteria enhances the antitumor activity of RT, which has important clinical ramifications.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Vancomycin -hydrochlorid aus Streptomyces orientalis, ≥900 μg per mg (as vancomycin base)
Sigma-Aldrich
Neomycin -trisulfat (Salz) Hydrat, powder
Sigma-Aldrich
Natriumpropionat, ≥99.0%
Sigma-Aldrich
Natriumbutyrat, ≥98.5% (GC)
Supelco
Metronidazol, analytical standard